ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ARQL
- CUSIP: 04269E10
- Web: www.arqule.com
Capitalization:- Market Cap: $86.8 million
- Outstanding Shares: 71,146,000
Average Prices:- 50 Day Moving Avg: $1.11
- 200 Day Moving Avg: $1.22
- 52 Week Range: $0.92 - $2.17
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.98
- P/E Growth: -0.52
Sales & Book Value:- Annual Revenue: $3.48 million
- Price / Sales: 24.94
- Book Value: $0.24 per share
- Price / Book: 5.08
Profitability:- EBIDTA: ($25,050,000.00)
- Net Margins: -482.44%
- Return on Equity: -95.33%
- Return on Assets: -66.00%
Debt:- Debt-to-Equity Ratio: 0.84%
- Current Ratio: 5.33%
- Quick Ratio: 5.33%
Misc:- Average Volume: 171,253 shs.
- Beta: 1.47
- Short Ratio: 4.66
Frequently Asked Questions for ArQule (NASDAQ:ARQL)
What is ArQule's stock symbol?
ArQule trades on the NASDAQ under the ticker symbol "ARQL."
How were ArQule's earnings last quarter?
ArQule, Inc. (NASDAQ:ARQL) released its earnings results on Wednesday, May, 3rd. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.00. ArQule had a negative net margin of 482.44% and a negative return on equity of 95.33%. During the same quarter in the prior year, the firm earned ($0.08) earnings per share. View ArQule's Earnings History.
When will ArQule make its next earnings announcement?
Who are some of ArQule's key competitors?
Some companies that are related to ArQule include Matinas BioPharma Holdings (MTNB), Genocea Biosciences (GNCA), Chromadex Corp (CDXC), OncoMed Pharmaceuticals (OMED), Pluristem Therapeutics (PSTI), Oramed Pharmaceuticals (ORMP), CytRx Corporation (CYTR), CTI BioPharma Corp. (CTIC), Tissue Regenix Group PLC (TRX), Vernalis plc (VER), aTyr Pharma (LIFE), GTx (GTXI), Infinity Pharmaceuticals (INFI), Galectin Therapeutics (GALT), Navidea Biopharmaceuticals (NAVB), Brainstorm Cell Therapeutics (BCLI), Abzena PLC (ABZA) and Silence Therapeutics plc (SLN).
Who are ArQule's key executives?
ArQule's management team includes the folowing people:
- Patrick J. Zenner, Independent Chairman of the Board
- Peter S. Lawrence, President, Chief Operating Officer
- Paolo Pucci, Chief Executive Officer, Director
- Robert J. Weiskopf, Chief Financial Officer, Treasurer
- Brian Schwartz M.D., Chief Medical Officer
- Timothy C. Barabe, Independent Director
- Susan L. Kelley M.D., Independent Director
- Ronald M. Lindsay Ph.D., Independent Director
- Michael D. Loberg Ph.D., Independent Director
- William G. Messenger D. Min., Independent Director
Who owns ArQule stock?
ArQule's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include First Eagle Investment Management LLC (15.34%), Vanguard Group Inc. (0.00%), NEA Management Company LLC (0.00%), Renaissance Technologies LLC (0.00%), FMR LLC (0.00%) and Geode Capital Management LLC (0.00%). Company insiders that own ArQule stock include Michael D Loberg, Paolo Pucci and Patrick J Zenner. View Institutional Ownership Trends for ArQule.
Who sold ArQule stock? Who is selling ArQule stock?
ArQule's stock was sold by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, FMR LLC, State of New Jersey Common Pension Fund D, Stoneridge Investment Partners LLC and Renaissance Technologies LLC. View Insider Buying and Selling for ArQule.
Who bought ArQule stock? Who is buying ArQule stock?
ArQule's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought ArQule stock in the last two years include Michael D Loberg, Paolo Pucci and Patrick J Zenner. View Insider Buying and Selling for ArQule.
How do I buy ArQule stock?
Shares of ArQule can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ArQule's stock price today?
One share of ArQule stock can currently be purchased for approximately $1.22.
MarketBeat Community Rating for ArQule (NASDAQ ARQL)MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for ArQule (NASDAQ:ARQL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for ArQule (NASDAQ:ARQL)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 3/1/2016 | Leerink Swann | Lower Price Target | Market Perform | $3.00 -> $2.50 | N/A |  |
| 12/27/2015 | Royal Bank Of Canada | Upgrade | Buy | | N/A | |
(Data available from 6/28/2015 forward)
Earnings History for ArQule (NASDAQ:ARQL)Earnings History by Quarter for ArQule (NASDAQ ARQL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/1/2017 | | | | | | | | |
| 5/3/2017 | Q1 2017 | ($0.11) | ($0.11) | | | View | Listen | |
| 3/7/2017 | Q4 2016 | ($0.10) | ($0.10) | $1.20 million | $1.19 million | View | Listen | |
| 11/7/2016 | Q316 | ($0.09) | ($0.08) | $1.10 million | $1.22 million | View | Listen | |
| 8/3/2016 | Q216 | ($0.08) | ($0.07) | $1.13 million | $1.07 million | View | N/A | |
| 5/4/2016 | Q116 | ($0.07) | ($0.08) | $1.63 million | $1.28 million | View | N/A | |
| 2/29/2016 | Q415 | ($0.06) | ($0.05) | $2.40 million | $2.80 million | View | Listen | |
| 11/4/2015 | Q315 | ($0.08) | ($0.04) | $2.60 million | $2.65 million | View | N/A | |
| 8/5/2015 | Q215 | ($0.08) | ($0.06) | $2.50 million | $3.04 million | View | N/A | |
| 5/6/2015 | Q115 | ($0.08) | ($0.07) | $1.98 million | $2.79 million | View | N/A | |
| 3/4/2015 | Q414 | ($0.13) | ($0.06) | $1.90 million | $3.02 million | View | N/A | |
| 11/10/2014 | Q314 | ($0.13) | ($0.10) | $2.20 million | $2.66 million | View | N/A | |
| 8/5/2014 | Q214 | ($0.13) | ($0.10) | $2.43 million | $2.90 million | View | N/A | |
| 5/7/2014 | Q114 | ($0.11) | ($0.11) | $2.29 million | $2.67 million | View | N/A | |
| 3/5/2014 | Q413 | ($0.13) | ($0.10) | $2.27 million | $2.28 million | View | N/A | |
| 10/31/2013 | Q313 | ($0.13) | ($0.10) | $2.77 million | $3.50 million | View | N/A | |
| 7/30/2013 | Q2 2013 | ($0.12) | ($0.11) | $3.84 million | $4.44 million | View | N/A | |
| 5/8/2013 | Q1 2013 | ($0.11) | ($0.09) | $3.78 million | $5.66 million | View | N/A | |
| 3/14/2013 | Q4 2012 | ($0.13) | ($0.09) | $5.17 million | $5.14 million | View | N/A | |
| 11/1/2012 | | ($0.07) | ($0.01) | | | View | N/A | |
| 8/2/2012 | | ($0.07) | ($0.01) | | | View | N/A | |
| 5/3/2012 | | ($0.07) | ($0.08) | | | View | N/A | |
| 3/1/2012 | | ($0.09) | $0.07 | | | View | N/A | |
| 11/10/2011 | | ($0.23) | ($0.04) | | | View | N/A | |
| 8/4/2011 | | ($0.19) | ($0.20) | | | View | N/A | |
| 5/5/2011 | | ($0.08) | ($0.03) | | | View | N/A | |
| 3/1/2011 | | ($0.15) | ($0.13) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for ArQule (NASDAQ:ARQL)2017 EPS Consensus Estimate: ($0.45)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.10) | ($0.10) | ($0.10) |
| Q2 2017 | 1 | ($0.11) | ($0.11) | ($0.11) |
| Q3 2017 | 1 | ($0.12) | ($0.12) | ($0.12) |
| Q4 2017 | 1 | ($0.12) | ($0.12) | ($0.12) |
(Data provided by Zacks Investment Research)
Dividend History for ArQule (NASDAQ:ARQL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ArQule (NASDAQ:ARQL)Insider Ownership Percentage: 9.00%
Institutional Ownership Percentage: 60.55%
Insider Trades by Quarter for ArQule (NASDAQ:ARQL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/17/2015 | Michael D Loberg | Director | Buy | 3,719 | $2.16 | $8,033.04 | |
| 12/16/2015 | Michael D Loberg | Director | Buy | 1,231 | $2.14 | $2,634.34 | |
| 12/15/2015 | Paolo Pucci | CEO | Buy | 1,283 | $2.16 | $2,771.28 | |
| 12/11/2015 | Paolo Pucci | CEO | Buy | 1,108 | $2.10 | $2,326.80 | |
| 12/11/2015 | Patrick J Zenner | Director | Buy | 2,300 | $2.15 | $4,945.00 | |
| 12/10/2015 | Paolo Pucci | CEO | Buy | 7,609 | $2.10 | $15,978.90 | |
| 3/11/2015 | Patrick J Zenner | Director | Buy | 10,625 | $2.32 | $24,650.00 | |
| 11/20/2014 | Paolo Pucci | CEO | Buy | 5,000 | $1.26 | $6,300.00 | |
| 11/14/2014 | Patrick J Zenner | Director | Buy | 20,830 | $1.20 | $24,996.00 | |
| 11/13/2014 | Susan L Kelley | Director | Buy | 50,000 | $1.20 | $60,000.00 | |
| 9/4/2014 | Paolo Pucci | CEO | Buy | 5,000 | $1.31 | $6,550.00 | |
| 5/23/2014 | Paolo Pucci | CEO | Buy | 5,000 | $1.40 | $7,000.00 | |
| 5/20/2014 | Paolo Pucci | CEO | Buy | 5,000 | $1.42 | $7,100.00 | |
| 3/17/2014 | Patrick Zenner | Director | Buy | 4,715 | $2.12 | $9,995.80 | |
| 3/13/2014 | Paolo Pucci | CEO | Buy | 10,000 | $2.10 | $21,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for ArQule (NASDAQ:ARQL)
Latest Headlines for ArQule (NASDAQ:ARQL)
| Source: |
|
| Date | Headline |
|---|
 | SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ArQule, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - June 26 at 4:08 PM |
 | ArQule (ARQL) Presents Preclinical Data for BTK Inhibitor, ARQ 531, at EHA
www.streetinsider.com - June 24 at 8:48 PM |
| ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)
finance.yahoo.com - June 23 at 4:15 PM |
| ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases
finance.yahoo.com - June 7 at 3:50 PM |
 | Analysts Expect ArQule, Inc. (ARQL) to Announce -$0.11 EPS
www.americanbankingnews.com - June 5 at 7:37 AM |
| ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - June 3 at 3:40 PM |
| ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - June 3 at 3:40 PM |
 | ArQule Stock Up 28% on Lab Data for B-Cell Lymphoma Drug
www.baystreet.ca - May 19 at 9:27 AM |
| ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)
finance.yahoo.com - May 18 at 12:06 PM |
| ArQule to Present Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 17 at 8:40 PM |
| ArQule, Inc. (ARQL) Short Interest Update
www.americanbankingnews.com - May 15 at 8:48 AM |
| -$0.11 EPS Expected for ArQule, Inc. (ARQL) This Quarter
www.americanbankingnews.com - May 9 at 6:16 PM |
| Leerink Swann Brokers Cut Earnings Estimates for ArQule, Inc. (ARQL)
www.americanbankingnews.com - May 8 at 8:26 AM |
| ArQule, Inc. (ARQL) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 4 at 7:06 PM |
| Edited Transcript of ARQL earnings conference call or presentation 3-May-17 1:00pm GMT
finance.yahoo.com - May 4 at 1:47 AM |
| ArQule, Inc. (ARQL) Issues Earnings Results, Meets Expectations
www.americanbankingnews.com - May 3 at 12:33 PM |
| Arqule Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 9:55 AM |
| ArQule reports 1Q loss
finance.yahoo.com - May 3 at 9:55 AM |
| Investor Network: ArQule, Inc. to Host Earnings Call
finance.yahoo.com - May 3 at 9:55 AM |
| ArQule (ARQL) Earns Daily Media Impact Rating of 0.13
www.americanbankingnews.com - May 2 at 8:16 AM |
| ArQule, Inc. (ARQL) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - May 1 at 11:56 AM |
| ArQule (ARQL) Receiving Somewhat Favorable News Coverage, Report Shows
www.americanbankingnews.com - April 27 at 4:38 PM |
| ArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531
finance.yahoo.com - April 26 at 9:10 AM |
| ArQule (ARQL) Earning Somewhat Positive Press Coverage, Report Finds
www.americanbankingnews.com - April 20 at 2:42 PM |
| ArQule To Report First Quarter 2017 Financial Results On May 3, 2017
finance.yahoo.com - April 19 at 9:15 AM |
| -$0.10 EPS Expected for ArQule, Inc. (ARQL) This Quarter
www.americanbankingnews.com - April 18 at 10:21 PM |
| Somewhat Favorable Media Coverage Somewhat Likely to Impact ArQule (ARQL) Stock Price
www.americanbankingnews.com - April 17 at 12:07 PM |
| Somewhat Critical Press Coverage Somewhat Likely to Effect ArQule (ARQL) Share Price
www.americanbankingnews.com - April 14 at 7:58 AM |
| ArQule (ARQL) Announces IND Application for BTK Inhibitor ARQ 531 Cleared by FDA - StreetInsider.com
www.streetinsider.com - April 11 at 8:03 AM |
| ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531
finance.yahoo.com - April 11 at 8:03 AM |
| ETFs with exposure to ArQule, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 8:07 AM |
 | FDA Nod For TSRO, Déjà Vu For ARQL, FOMX Plunges On Trial Data, SELB Abuzz - RTT News
www.rttnews.com - March 28 at 3:38 PM |
| ArQule to Present at the 16th Annual Needham Healthcare Conference on April 4, 2017
finance.yahoo.com - March 28 at 10:32 AM |
| Pre-Open Movers 03/27: (HTGM) (WFT) (SNAP) Higher; (FOMX) (ARQL) (MEET) Lower (more...)
www.streetinsider.com - March 27 at 3:42 PM |
 | ArQule Announces Top-Line Results of Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan
us.rd.yahoo.com - March 27 at 8:30 AM |
| Zacks: ArQule, Inc. (ARQL) Given $1.30 Consensus Price Target by Analysts
www.americanbankingnews.com - March 23 at 10:43 AM |
| ARQULE INC Financials
finance.yahoo.com - March 15 at 3:54 PM |
| ARQULE INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 9 at 9:15 PM |
| Edited Transcript of ARQL earnings conference call or presentation 7-Mar-17 2:00pm GMT
finance.yahoo.com - March 8 at 1:41 AM |
| EARNINGS SUMMARY: Details of ArQule Inc. Q4 Earnings Report
www.rttnews.com - March 7 at 3:40 PM |
 | ArQule's (ARQL) CEO Paolo Pucci on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 7 at 3:40 PM |
| ArQule Reports Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 7 at 3:40 PM |
| Q4 2016 ArQule Inc Earnings Release - Before Market Open
us.rd.yahoo.com - March 7 at 3:40 PM |
| ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 7 at 8:28 AM |
| ArQule To Report Fourth Quarter and Year End 2016 Financial Results On March 7, 2017
finance.yahoo.com - February 24 at 12:37 PM |
 | ArQule Liver Cancer Drug Fails Phase 3 (ARQL)
www.investopedia.com - February 20 at 3:32 PM |
| ArQule Liver Cancer Drug Fails Phase 3 Trial
www.investopedia.com - February 20 at 3:32 PM |
| ArQule (ARQL), Daiichi Sankyo Phase 3 Study of Tivantinib Misses ... - StreetInsider.com
www.streetinsider.com - February 18 at 3:35 PM |
| ArQule (ARQL), Daiichi Sankyo Phase 3 Study of Tivantinib Misses Primary Endpoint
www.streetinsider.com - February 18 at 9:50 AM |
| ArQule, Inc. (ARQL)
seekingalpha.com - February 18 at 9:50 AM |
ArQule (ARQL) Chart for Wednesday, June, 28, 2017
